Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Phase IIIa Randomized, Controlled Study to Assess the Immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered as a 3-dose Primary Immunization Course Before 6 Months of Age
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10315
- GSK Investigational Site
-
Berlin, Germany, 13055
- GSK Investigational Site
-
Berlin, Germany, 12627
- GSK Investigational Site
-
Berlin, Germany, 12679
- GSK Investigational Site
-
Berlin, Germany, 14197
- GSK Investigational Site
-
Berlin, Germany, 13409
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Mannheim, Baden-Wuerttemberg, Germany, 68167
- GSK Investigational Site
-
Marbach, Baden-Wuerttemberg, Germany, 71672
- GSK Investigational Site
-
-
Bayern
-
Noerdlingen, Bayern, Germany, 86720
- GSK Investigational Site
-
Tutzing, Bayern, Germany, 82327
- GSK Investigational Site
-
-
Hessen
-
Wiesbaden, Hessen, Germany, 65205
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Germany, 18146
- GSK Investigational Site
-
Waren, Mecklenburg-Vorpommern, Germany, 17192
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Bad Oeynhausen, Nordrhein-Westfalen, Germany, 32549
- GSK Investigational Site
-
Erkrath, Nordrhein-Westfalen, Germany, 40699
- GSK Investigational Site
-
Goch, Nordrhein-Westfalen, Germany, 47574
- GSK Investigational Site
-
Heiligenhaus, Nordrhein-Westfalen, Germany, 42579
- GSK Investigational Site
-
Minden, Nordrhein-Westfalen, Germany, 32427
- GSK Investigational Site
-
Moenchengladbach, Nordrhein-Westfalen, Germany, 41061
- GSK Investigational Site
-
Moenchengladbach, Nordrhein-Westfalen, Germany, 41236
- GSK Investigational Site
-
Muenster, Nordrhein-Westfalen, Germany, 48159
- GSK Investigational Site
-
Oberhausen, Nordrhein-Westfalen, Germany, 46145
- GSK Investigational Site
-
Willich, Nordrhein-Westfalen, Germany, 47877
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Frankenthal, Rheinland-Pfalz, Germany, 67227
- GSK Investigational Site
-
Gerolstein, Rheinland-Pfalz, Germany, 54568
- GSK Investigational Site
-
Mainz, Rheinland-Pfalz, Germany, 55131
- GSK Investigational Site
-
Trier, Rheinland-Pfalz, Germany, 54294
- GSK Investigational Site
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04178
- GSK Investigational Site
-
Stollberg, Sachsen, Germany, 09366
- GSK Investigational Site
-
-
Thueringen
-
Lobenstein, Thueringen, Germany, 07356
- GSK Investigational Site
-
Neuhaus am Rennweg, Thueringen, Germany, 98724
- GSK Investigational Site
-
Weimar, Thueringen, Germany, 99425
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Male or female between, and including, 8 and 16 weeks (56-118 days) of age at the time of the first vaccination, free of obvious health problems and with written informed consent obtained from the parent/guardian of the subject.
Exclusion criteria:
- Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Planned administration/ administration of a licensed vaccine not foreseen by the study protocol during the period starting from one month before the first dose of vaccine(s) and during the entire study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
1 month post-dose 3: Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations >= 0.20 µg/mL
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
1 month post dose 3: For all vaccine pneumococcal serotypes: Opsono titres
|
|
Antibody (Ab) concns >= 0.05 µg/mL
|
|
Ab concns to protein D and seropositivity (S+) status
|
|
S+/seroprotection status to antigens in DTPa-HBV-IPV/Hib vaccine
|
|
After each vaccination, occurrence of: solicited local, general symptoms within 4 days
|
|
Unsolicited adverse events within 31 days, SAEs (whole study period)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 105554
- 2005-003299-40 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Study Data/Documents
-
Study Protocol
Information identifier: 105554Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 105554Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 105554Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 105554Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 105554Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 105554Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.